Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center
Houston, TX
Accepting patients
CARE Study
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results
Accepting patients
LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers
- Observational Trial